Peptide News Digest

#William-Blair

2 stories

Industry · View digest

Kailera Therapeutics (NASDAQ: KLRA) Received Sweeping Positive Analyst Coverage Following Its August 12 Q2 2026 Earnings Report Confirming an Active Investigational New Drug (IND) Application With the FDA for Ribupatide Oral (KAI-9531-T) and Global Phase 3 Obesity Trials Planned for H1 2027, With 6 Analysts Averaging a Strong Buy Rating and a $42.60 12-Month Price Target (Representing 82.83% Upside From the $17.95-$19.50 Trading Range on August 13-14), Including TD Cowen at Buy With a $57 Price Target, Evercore ISI at Outperform, and William Blair at Outperform; The Company Holds Cash, Cash Equivalents, and Marketable Securities Expected to Support Execution of Multiple Clinical Milestones With Runway Into Mid-2028; Ribupatide Is a Once-Weekly GLP-1/GIP Dual Agonist Peptide That Reached 23.6% Mean Weight Loss at 8 mg Over 36 Weeks in Phase 2 Injection Trial, With the Oral Formulation Reaching Up to 12.1% Weight Loss and 38.6% of Participants Achieving ≥15% Loss in Hengrui's Phase 2 Trial

Kailera Therapeutics (NASDAQ: KLRA) received sweeping positive analyst coverage following its August 12, 2026 Q2 2026 earnings report. Kailera confirmed an active Investigational New Drug (IND) application with the FDA for ribupatide oral (KAI-9531-T) and global Phase 3 obesity trials planned for H1 2027. Analyst response: according to 6 analysts, the average rating for KLRA stock is Strong Buy, with a 12-month average price target of $42.60 representing 82.83% upside from the $17.95-$19.50 trading range on August 13-14. Named ratings include TD Cowen at Buy with a $57 price target, Evercore ISI at Outperform, and William Blair at Outperform. The company holds cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028. Ribupatide mechanism: a once-weekly GLP-1/GIP dual agonist peptide (mechanistically similar to Eli Lilly's tirzepatide) with the ribupatide injection Phase 2 trial reaching 23.6% mean weight loss at 8 mg over 36 weeks, and the oral formulation reaching up to 12.1% weight loss with 38.6% of participants achieving at least 15% loss at Week 26 in Hengrui's Phase 2 trial. The Phase 2b high-dose injection trial in obesity is fully enrolled with data anticipated in mid-2027.

Industry · View digest

TRIUMPH-1 Analyst Reaction (May 22): LLY +1% Premarket, William Blair Sees High-BMI Confinement on 11.3% Discontinuation + Dysesthesia Signal, Mahmood 'Very Impressive' Pending ADA Data

Day-after analyst reaction to Lilly's May 21 TRIUMPH-1 topline split between efficacy enthusiasm and tolerability caution. LLY shares rose roughly 1% in Thursday premarket trading. William Blair noted that retatrutide's 11.3% discontinuation rate on 12 mg plus the dysesthesia signal (skin tingling, 12.5% of 12 mg participants — a finding not reported in Phase 2 data) probably confines the drug to higher-BMI patient populations, with tirzepatide remaining the volume agent at the moderate-BMI tier. BMO Capital Markets specifically flagged the dysesthesia signal as worth monitoring in subsequent readouts and the TRIUMPH-4 follow-on detail. Manak Mahmood at Pharma Intelligence framed the data as 'very impressive' but noted ADA 2026 full data presentation in two weeks will be critical for the obesity-market positioning. The GI side-effect profile at 12 mg — nausea 42.4%, vomiting 25.3%, diarrhea 32.0% — is the tolerability gap that prescribers will weigh against the efficacy gain over tirzepatide.